Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.

Hormone Replacement Therapy in Cancer Survivors - Review of the Literature. Pathol Oncol Res. 2019 Jan 08;: Authors: Deli T, Orosz M, Jakab A Abstract Rapid advance in oncology leads to increasing survival of oncologic patients. More and more of them live long enough to reach either the natural age of menopause or, as a side effect of their oncotherapy, experience the cessation of gonadal function, leading to premature ovarian insufficiency, with disturbing vasomotor symtoms and long-term negative cardiovascular and skeletal effects. Thus, an ever increasing number of cancer survivors search endocrinologic help in the form of hormone replacement therapy (HRT). The misinterpretation of the WHI (Women's Health Initiative) Study has lead to an irrational fear of female hormone replacement, both by the general population and medical professionals. It has seemed the logical and safe conclusion to many physicians to avoid HRT, supposing that this attitude definitely causes no harm, whereas the decision of prescribing estrogen alone or with progestins might bear oncologic and thromboembolic risks and may even lead to litigation in case of a potentially related complication. However, it was known even before the WHI results that premature menopause and hypogonadism decreases the life expectancy of women by years through its skeletal and cardiovascular effects, and this negative effect correlates with the length of the hypoestrogenaemic period. Therefore, the den...
Source: Pathology Oncology Research - Category: Pathology Authors: Tags: Pathol Oncol Res Source Type: research

Related Links:

Publication date: Available online 7 July 2020Source: The American Journal of SurgeryAuthor(s): Kurt S. Schultz, Susanna W.L. de Geus, Teviah E. Sachs, Ryan B. Morgan, Sing Chau Ng, David McAneny, Jennifer F. Tseng
Source: The American Journal of Surgery - Category: Surgery Source Type: research
The objectives of this paper are the presentation of a sample of patients with PC undergoing treatment with androgen deprivation therapy (ADT) in usual clinical practice and the determination of parameters associated with the development of resistance to castration (CRPC). MATERIAL AND METHODS: Multicenter, observational, retrospective study that analyzes patients treated with ADT from January 2016 to January 2017. Descriptive analysis of the most relevant clinical variables and univariante analysis and progression times by Kaplan-Meier test. RESULTS: Sample of 952 patients. At PC diagnosis median age 74 years. Med...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Authors: González-Vilas D, Monteagudo B, González-Martín C, Ramírez-Santos A, Campo-Cerecedo F Abstract 53 year old renal transplanted male with secondary amyloidosis to Crohn´sdisease, sent to Dermatology given the presence of multiple red-purple or hyperkeratotic... PMID: 32633255 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
CONCLUSIONS: We concluded that despite the fact that the plasmacytoid variant of BC is rare, it is important to take into account the pathologic and clinical features of this tumor in order to manage the optimal treatment of this poor prognosis cancer. PMID: 32633253 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Patient age, breast density, and radiation exposure are among the strongest,...Read more on AuntMinnie.comRelated Reading: Earlier breast screening benefits women with childhood cancer Interval breast cancers have unique characteristics Breast imagers can help identify women for genetic testing Women want breast cancer risk info from radiologists Many women at risk for breast cancer don't take action
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
CONCLUSION: To address flaws in conceptualisation and the resulting gaps in knowledge, we suggest a definition and a theoretical framework that are suited to allow heterogeneity in the field, but enables the development of sound interventions, as well as facilitate the interpretation of intervention effectiveness. PMID: 32631110 [PubMed - in process]
Source: European Journal of General Practice - Category: Primary Care Tags: Eur J Gen Pract Source Type: research
Publication date: 30 August 2020Source: International Journal of Pharmaceutics, Volume 586Author(s): Joo Young Lee, Young-um Jo, Heejun Shin, Jonghwan Lee, Soon Uk Chae, Soo Kyung Bae, Kun Na
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: Levels of TF-positive EVs, D-dimer and sP-selectin are able to discriminate between unprovoked VTD patients not related to cancer and cancer patients not associated with VTD. These results could lead to the application of EVs as biomarkers of both diseases.Key Messages: Circulating EVs, specifically TF-positive EVs, in combination with plasmatic markers of hypercoagulable states, such as D-dimer, sP-selectin and antigen TF, are able to discriminate between cancer patients without thrombosis and patients with unprovoked VTD. Research fields could be opened. Future studies will assess if these biomarkers togethe...
Source: Annals of Medicine - Category: Internal Medicine Tags: Ann Med Source Type: research
Abstract The idiopathic inflammatory myopathies, particularly dermatomyositis, are associated with an increased risk of cancer. Lung, ovarian, breast, colon, prostate, and cervical cancers, and hematologic malignancies, are among the most common associated cancers. Risk stratification for cancer in patients with myositis is based on clinical risk factors/red flags, myositis clinical subtypes, and myositis-specific autoantibodies. Clinical risk factors include older age at disease onset, male gender, dysphagia, acute onset/refractory myositis, cutaneous ulceration, necrosis/vasculitis, and elevated inflammatory mar...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Rheum Dis Clin North Am Source Type: research
Abstract Systemic lupus erythematosus is associated with a small overall increased cancer risk compared with the general population. This risk includes a 4-fold increased risk of non-Hodgkin lymphoma, but a decreased risk of other cancers (such as breast cancer). The pathophysiology underlying the increased risk of hematologic cancer is not fully understood, but many potential mechanisms have been proposed, including dysfunction of the tumor necrosis factor and other pathways. A decreased risk of breast, ovarian, and endometrial cancer might be driven by hormonal factors or lupus-related antibodies, but these link...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Rheum Dis Clin North Am Source Type: research
More News: Adenocarcinoma | Bladder Cancer | Brain | Brain Cancers | Brain Tumor | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinosarcoma | Cardiology | Cardiovascular | Cervical Cancer | Colorectal Cancer | Endocrinology | Endometrial Cancer | Gastric (Stomach) Cancer | Gastroenterology | Glioma | Heart | Hepatocellular Carcinoma | Hormone Replacement Therapy | Hormones | Kidney Cancer | Leiomyosarcoma | Liver Cancer | Low Testosterone | Lung Cancer | Melanoma | Men | Menopause | Neurology | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Pathology | Sarcomas | Skin Cancer | Squamous Cell Carcinoma | Study | Thyroid | Thyroid Cancer | Urology & Nephrology | Women